Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMFX9O6)

• Drug Name: SM-101 Drug Info
• Synonyms: SMP-534

Indication

Disease Entry	ICD 11	Status	REF
Idiopathic thrombocytopenic purpura	3B64.10	Approved (orphan drug)	[1]
Systemic lupus erythematosus	4A40.0	Phase 2	[2]
Diabetic nephropathy	GB61.Z	Preclinical	[3]

• Cross-matching ID:
  PubChem CID: 445629
  TTD Drug ID: DMFX9O6

Molecule-Related Drug Atlas

Drug(s) Targeting MAP kinase p38 (MAPK12)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
VX-745	DMJAEG6	Alzheimer disease	8A20	Phase 2	[4]
ARRY-797	DMJ48AB	Dilated cardiomyopathy	BC43.0	Phase 2	[5]
KC706	DMBX6C7	Cardiovascular disease	BA00-BE2Z	Discontinued in Phase 2	[6]
SB 235699	DMNH8XU	Psoriasis vulgaris	EA90	Discontinued in Phase 1	[7]
RO-316233	DMAGLPW	Discovery agent	N.A.	Investigative	[8]
Bisindolylmaleimide-I	DMOQJZC	Discovery agent	N.A.	Investigative	[8]
4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole	DMN9YOB	Discovery agent	N.A.	Investigative	[9]
CI-1040	DMF3DZX	Discovery agent	N.A.	Investigative	[8]
AMP-PNP	DMTOK1D	Discovery agent	N.A.	Investigative	[10]
KN-62	DMLZ89P	Discovery agent	N.A.	Investigative	[8]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Immunoglobulin gamma Fc receptor IIA (FCGR2A)	TTXT21W	FCG2A_HUMAN	Antagonist	[1]
MAP kinase p38 (MAPK12)	TTYT93M	MK12_HUMAN	Inhibitor	[3]

References

• [1] Emerging drugs for idiopathic thrombocytopenic purpura in adults. Expert Opin Emerg Drugs. 2008 Jun;13(2):237-54.
• [2] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [3] Agents in development for the treatment of diabetic nephropathy. Expert Opin Emerg Drugs. 2008 Sep;13(3):447-63.
• [4] P38 MAP kinase inhibitors as potential therapeutics for the treatment of joint degeneration and pain associated with osteoarthritis. J Inflamm (Lond). 2008 Dec 4;5:22.
• [5] Array BioPharmas ARRY-797 Meets Primary Endpoint in Clinical Proof of Concept Trial in Osteoarthritis Patients Whose Pain is Poorly Controlled by NSAIDs
• [6] KC706, an Oral p38 MAP Kinase Inhibitor, Increases HDL-C. Circulation. 2007;116:II_126.
• [7] Synthesis and structure-activity relationship of aminobenzophenones. A novel class of p38 MAP kinase inhibitors with high antiinflammatory activity. J Med Chem. 2003 Dec 18;46(26):5651-62.
• [8] Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105.
• [9] Optimization of protein kinase CK2 inhibitors derived from 4,5,6,7-tetrabromobenzimidazole. J Med Chem. 2004 Dec 2;47(25):6239-47.
• [10] The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.